News brief­ing: Amar­in's pan­el could put Vas­cepa patents in jeop­ardy; San­thera nabs a Duchenne drug

Amarin’s fish oil em­pire may be slip­ping out of its grasp.

On Wednes­day, in the lat­est twist in a long le­gal bat­tle, the ap­peal pan­el of judges was an­nounced for the patent dis­pute be­tween Amarin with two gener­ic drug­mak­ers that are look­ing to make off-brand de­ci­sion. No rul­ing has yet been made — the hear­ing starts at 10:30 this morn­ing — but an­a­lysts be­lieved that the de­ci­sion could come down to which judges were cho­sen, and that these judges may be un­like­ly to de­cide in Amarin’s fa­vor. The stock fell 17% pre-mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.